NASDAQ · AUTL
Autolus Therapeutics plc
$1.58-$0.05 (-3.07%)
Autolus Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
Loading market information…
NASDAQ · ALLO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Allogene Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Allogene Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$0.280.0% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -$0.28+17.65% vs estimate | $22.00K+83.33% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.27+20.59% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
30 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.58-$0.05 (-3.07%)
Autolus Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
$1.46-$0.04 (-2.67%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
$2.17$0.00 (0.0%)
Fate Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.82% below the high.
$7.44-$0.03 (-0.4%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
$1.17-$0.09 (-7.14%)
Cellectis S.A.’s quoted price sits in the lower half of its reported 52-week range, 78.53% below the high.
$8.53-$0.13 (-1.5%)
Atara Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.46% below the high.
$0.45-$0.04 (-9.07%)
Caribou Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.43% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
